Horizon Therapeutics Public (NASDAQ:HZNP) Sees Strong Trading Volume

Shares of Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) saw unusually-high trading volume on Thursday . Approximately 95,070 shares were traded during mid-day trading, a decline of 94% from the previous session’s volume of 1,522,410 shares.The stock last traded at $67.59 and had previously closed at $66.96.

Analyst Upgrades and Downgrades

HZNP has been the topic of a number of research reports. Morgan Stanley dropped their price objective on Horizon Therapeutics Public from $135.00 to $90.00 and set an “overweight” rating on the stock in a research note on Thursday. SVB Leerink downgraded Horizon Therapeutics Public from an “outperform” rating to a “market perform” rating in a research note on Thursday. Oppenheimer reaffirmed a “buy” rating and set a $140.00 target price on shares of Horizon Therapeutics Public in a research report on Friday, July 8th. Wells Fargo & Company reaffirmed a “buy” rating and set a $133.00 target price on shares of Horizon Therapeutics Public in a research report on Friday, April 8th. Finally, StockNews.com lowered Horizon Therapeutics Public from a “buy” rating to a “hold” rating in a research report on Friday. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Horizon Therapeutics Public presently has an average rating of “Moderate Buy” and a consensus target price of $117.22.

Horizon Therapeutics Public Stock Up 3.9 %

The stock has a market capitalization of $16.03 billion, a price-to-earnings ratio of 21.48, a price-to-earnings-growth ratio of 1.13 and a beta of 1.12. The company has a quick ratio of 3.30, a current ratio of 4.05 and a debt-to-equity ratio of 0.52. The firm has a 50-day moving average of $83.03 and a two-hundred day moving average of $93.34.

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) last posted its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $1.07 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.29). The business had revenue of $876.40 million for the quarter, compared to analyst estimates of $938.82 million. Horizon Therapeutics Public had a net margin of 20.06% and a return on equity of 27.90%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.62 earnings per share. As a group, sell-side analysts anticipate that Horizon Therapeutics Public Limited will post 5.68 earnings per share for the current year.

Insider Activity at Horizon Therapeutics Public

In other Horizon Therapeutics Public news, EVP Andy Pasternak sold 4,850 shares of the business’s stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $82.57, for a total value of $400,464.50. Following the transaction, the executive vice president now owns 34,047 shares in the company, valued at $2,811,260.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Horizon Therapeutics Public news, EVP Andy Pasternak sold 4,850 shares of the business’s stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $82.57, for a total value of $400,464.50. Following the transaction, the executive vice president now owns 34,047 shares in the company, valued at $2,811,260.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Timothy P. Walbert sold 25,000 shares of the business’s stock in a transaction dated Friday, May 20th. The shares were sold at an average price of $90.00, for a total value of $2,250,000.00. Following the completion of the transaction, the chief executive officer now owns 460,549 shares in the company, valued at approximately $41,449,410. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 98,384 shares of company stock valued at $8,934,633. Company insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Johnson Financial Group Inc. bought a new stake in shares of Horizon Therapeutics Public during the 4th quarter worth about $25,000. UMB Bank N A MO bought a new stake in shares of Horizon Therapeutics Public during the 4th quarter worth about $34,000. Covestor Ltd bought a new stake in shares of Horizon Therapeutics Public during the 4th quarter worth about $37,000. Citizens National Bank Trust Department bought a new stake in shares of Horizon Therapeutics Public during the 4th quarter worth about $38,000. Finally, Tcwp LLC bought a new stake in shares of Horizon Therapeutics Public during the 1st quarter worth about $41,000. Hedge funds and other institutional investors own 88.39% of the company’s stock.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Featured Articles

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.